Home Overview Press Room Blog Publications For Students about us
Search

August 4, 2005 Newsletter

Genetic Crossroads
August 4th, 2005


ANNOUNCEMENT: CGS RECEIVES "LOCAL HERO" AWARD FROM SAN FRANCISCO BAY GUARDIANGenetic CrossroadsAugust 4th, 2005
Senator Frist's stem cell shiftGenetic CrossroadsAugust 4th, 2005
Dog cloning reopens controversyGenetic CrossroadsAugust 4th, 2005
UPDATE: PUBLIC INTEREST CHALLENGES TO CALIFORNIA STEM CELL INSTITUTE CONTINUEGenetic CrossroadsAugust 4th, 2005
RESOURCESGenetic CrossroadsAugust 4th, 2005
LEGISLATIVE UPDATESGenetic CrossroadsAugust 4th, 2005
TECHNOLOGICAL DEVELOPMENTSGenetic CrossroadsAugust 4th, 2005
IN THE NEWSGenetic CrossroadsAugust 4th, 2005
CGS NEWSGenetic CrossroadsAugust 4th, 2005
One Step Forward, Two Steps Backby Osagie ObasogieSan Francisco ChronicleJuly 5th, 2005NitroMed's BiDil recently received FDA approval as the first drug targeted exclusively for a racial group. Does this make sense? Is this good science? BiDil has been met with both celebration and admonition. At the same time, accusations of racial opportunism are flying left and right.

ESPAÑOL | PORTUGUÊS | Русский

home | overview | blog | publications| about us | donate | newsletter | press room | privacy policy

CGS • 1122 University Ave, Suite 100, Berkeley, CA 94702 • • (p) 1.510.665.7760 • (F) 1.510.665.8760